Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
NCT02654665 on ClinicalTrials.gov · last registry update 2018-01-30
A small phase 3 — 36 participants, against a typical 424. The sponsor logged completion for December 2017. Primary outcome, as filed: Improvement in NASH. liraglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Changi General Hospital
- Sponsor type
- Other
- Enrollment
- 36
- Started
- 2014-03
- Primary completion
- 2017-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Improvement in NASH
Conditions studied
Non-alcoholic Fatty Liver Disease (NAFLD) · Weight Loss · Non-alcoholic Steatohepatitis (NASH)
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.